Trial Profile
A Pilot Study of PLX3397 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastasis and High Circulating Tumor Cell (CTC) Counts
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Daiichi Sankyo Inc; Plexxikon
- 11 Oct 2019 Status changed to discontinued.
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.